Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LinCAR-T 19
- Development stage
- Unknown
- Lead developer
- Juventas Cell Therapy
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
LinCAR-T 19 is an investigational CAR-T cell therapy targeting CD19, a surface antigen highly expressed on malignant B cells in various hematological cancers, most notably B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphomas. CAR-T therapies genetically engineer T cells to express a chimeric antigen receptor specific for CD19, enabling direct recognition and lysis of CD19-expressing cancer cells. This approach is a form of adoptive cellular immunotherapy and has revolutionized treatment for refractory or relapsed B-cell malignancies. LinCAR-T 19 represents a specific formulation or platform within the CD19-targeting CAR-T therapy category. While approved CD19 CAR-T therapies exist, LinCAR-T 19 is not among the currently FDA-approved products and appears to be in earlier stages of clinical investigation.
- Brand names
- LinCAR-T 19LinCAR-T19LinCAR-T-19
- Other names
- LinCAR-T 19LinCAR-T19LinCAR-T-19
02
Targets
Beyond the preview
Go deeper on LinCAR-T 19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LinCAR-T 19.